News
AGNPF
0.052
NaN%
--
Weekly Report: what happened at AGNPF last week (1124-1128)?
Weekly Report · 6d ago
Algernon Health Secures CAD $210,000 in Private Placement to Boost Alzheimer’s Program
TipRanks · 6d ago
Algernon Health Raises $210,000 in Second Private Placement
Reuters · 11/29 00:53
ALGERNON CLOSES SECOND TRANCHE OF PRIVATE PLACEMENT FINANCING
Reuters · 11/29 00:51
Algernon Pharmaceuticals Partners with AMI for U.S. Neuroimaging Clinics
TipRanks · 11/24 23:43
Weekly Report: what happened at AGNPF last week (1117-1121)?
Weekly Report · 11/24 10:22
Algernon Health Closes First Tranche of Private Placement Financing
TipRanks · 11/17 17:14
Weekly Report: what happened at AGNPF last week (1110-1114)?
Weekly Report · 11/17 10:22
ALGERNON CLOSES FIRST TRANCHE OF ITS RECENTLY ANNOUNCED PRIVATE PLACEMENT FINANCING
Reuters · 11/15 00:55
Weekly Report: what happened at AGNPF last week (1103-1107)?
Weekly Report · 11/10 10:19
Algernon Health Announces Private Placement and Share Structure Alteration
TipRanks · 11/06 17:38
Algernon Pharmaceuticals announces $500,000 private placement
TipRanks · 11/06 13:28
Algernon Health Announces $500,000 Private Placement at $0.07 Per Unit
Reuters · 11/06 12:24
ALGERNON HEALTH ANNOUNCES PRIVATE PLACEMENT
Reuters · 11/06 12:04
Weekly Report: what happened at AGNPF last week (1027-1031)?
Weekly Report · 11/03 10:20
Weekly Report: what happened at AGNPF last week (1020-1024)?
Weekly Report · 10/27 10:23
Weekly Report: what happened at AGNPF last week (1013-1017)?
Weekly Report · 10/20 10:20
Psychedelic: Needham initiates coverage of atai, GH Research, MindMed
TipRanks · 10/16 15:30
Algernon Pharmaceuticals Rebrands as Algernon Health to Focus on Alzheimer’s Diagnostics
Barchart · 10/16 13:54
More
Webull provides a variety of real-time AGNPF stock news. You can receive the latest news about Algernon Health through multiple platforms. This information may help you make smarter investment decisions.
About AGNPF
Algernon Health Inc., formerly Algernon Pharmaceuticals Inc., is a Canadian healthcare company. The Company is focused on the provision of brain-specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. It is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company also owns a 20% equity position in Seyltx, a private U.S-based drug development company advancing a chronic cough drug called Ifenprodil.